{"pharmacology": {"name": "Pharmacology", "children": [{"name": "Pharmacodynamics", "children": [{"name": "Mechanism of action", "children": [{"name": "Serotonin Receptor Studies"}, {"name": "Paroxetine Bindeing"}, {"name": "SSRIs Effect on Fear"}, {"name": "SSRIs Effect on Neural Processing of Emotional Cues"}, {"name": "Serotonin Binding and Receptor Studies"}, {"name": "Astrocyte Receptors"}, {"name": "Repeated SSRIs Exposures Effects on Dopamine Receptors"}, {"name": "Neurochemical and Electrophysiological Correlates of SSRIs"}, {"name": "SSRIs for OCD-like behaviors"}, {"name": "SSRIs in Model Organisms ( C. Elegans and Drosophilia)"}, {"name": "Tryptophan Depletion in Depression"}]}, {"name": "Animal Models of Disorders", "children": [{"name": "The Chronic Unpredictable Mild Stress Model of Depression"}, {"name": "SSRIs in Forced Swimming Test"}, {"name": "SSRIs Effect on Response Inhibition"}, {"name": "Olfactory Bulbectomized (OB) Rat Model for Depression"}]}, {"name": "OtherPharmacodynamics", "children": [{"name": "SSRI Neuroscience"}, {"name": "SSRIs Effects on Ion Channels"}, {"name": "Methylenedioxymethamphetamine (MDMA) Effects on Serotonin"}, {"name": "Pulmonary Hypertension"}, {"name": "Sex differences in SSRI Effects in Depression"}, {"name": "Paroxetines Therapeutic Potential as G Protein-coupled Receptor Kinase 2 (GRK2) Inhibitor for Cardiovascular Diseases"}, {"name": "Serotonin and Dopamine Release and Uptake Dynamics"}, {"name": "SSRIs and Galanin in Depression"}, {"name": "SSRIs Cellular Distribution"}, {"name": "Treatment of Paroxetine Induced Sexual Dysfunction"}]}]}, {"name": "Pharmacokinetics", "children": [{"name": "SSRIs and the Cytochrome P450 System"}, {"name": "(Sertraline) Drug Delivery"}]}, {"name": "Pharmacogenetics", "children": [{"name": "Serotonin Transporter Gene and Antidepressant Response"}, {"name": "Genotype Mediated Response to SSRIs"}]}, {"name": "Analytical Methods", "children": [{"name": "Quantification of SSRIs in Biological Samples"}, {"name": "Novel Compounds Synthesis and Antidepressant Potential"}]}, {"name": "Biomarker Search", "children": [{"name": "Paroxetine Bindeing"}, {"name": "SSRIs and Inflammation"}, {"name": "SSRIs Effect on Brain-derived Neurotrophic Factor (BDNF) Levels in Depressive Patients"}, {"name": "Loudness Dependence of Auditory Evoked Potentials (LDAEP) as Biomarker for Depression"}]}, {"name": "OtherPharmacology", "children": [{"name": "Risks of Prenatal Exposure"}, {"name": "SSRI Synthesis"}, {"name": "SSRIs Effects on Neuroendocrine System"}, {"name": "Pharmacological Perspectives on Antidepressants"}]}]}, "indications": {"name": "Indications", "children": [{"name": "Disorders", "children": [{"name": "Depression", "children": [{"name": "Pediatric Depression"}, {"name": "The Chronic Unpredictable Mild Stress Model of Depression"}, {"name": "SSRIs in Forced Swimming Test"}, {"name": "Sequenced Depression Treatment"}, {"name": "Post-Stroke SSRI Use"}, {"name": "SSRIs and Inflammation"}, {"name": "Escitalopram for Depression"}, {"name": "SSRIs and Cardiovascular Pathology"}, {"name": "SSRIs for Bipolar Depression"}, {"name": "SSRIs for Depression in Parkinsons Patients"}, {"name": "SSRIs Effect on Sleep in Depressed Patients"}, {"name": "SSRIs for Depression in Diabetes Patients"}, {"name": "SSRIs for Premenstrual Dysphoric Disorder (PMDD)"}, {"name": "SSRIs for Depression with Cognitive Impairment"}, {"name": "SSRIs for Depression in in Epileptic Patients"}, {"name": "Sertraline for Depression"}, {"name": "Depression Treatment Review"}, {"name": "Agomelatin for Depression"}, {"name": "Geriatric Depression"}, {"name": "Citalopram for Depression"}, {"name": "Depression in Hepatitis Patients"}, {"name": "SSRIs and Augmentation for Treatment Resistant Depression"}, {"name": "SSRIs for Depression after Traumatic Brain Injury"}, {"name": "Sex differences in SSRI Effects in Depression"}, {"name": "Transcranial Direct Current Stimulation (tDCS) for Depression"}, {"name": "SSRIs for Depression in Cancer"}, {"name": "SSRIs Effect on Brain-derived Neurotrophic Factor (BDNF) Levels in Depressive Patients"}, {"name": "SSRIs for Postpartum Depression"}, {"name": "SSRIs for Depression in Kidney Disease Patients"}, {"name": "Vilazodone for Depression"}, {"name": "SSRIs for Depression in and Treatment of Multiple Sclerosis"}, {"name": "SSRIs for Depression in Chronic Obstructive Pulmonary Disease (COPD) Patients"}, {"name": "Folate for Depression"}, {"name": "Tryptophan Depletion in Depression"}, {"name": "SSRIs for Depression in HIV-positive Patients"}, {"name": "Loudness Dependence of Auditory Evoked Potentials (LDAEP) as Biomarker for Depression"}, {"name": "Novel Compounds Synthesis and Antidepressant Potential"}, {"name": "Exercise for Depression"}, {"name": "SSRIs and Galanin in Depression"}, {"name": "Psychotic Depression (STOP-PD Study)"}, {"name": "Childhood Abuse and Depression Treatment Response"}, {"name": "Psilocybin for Depression"}]}, {"name": "Anxiety", "children": [{"name": "SSRIs Effect on Fear"}, {"name": "SSRIs for Panic Disorder"}, {"name": "SSRIs for Generalized Anxiety Disorder (GAD)"}, {"name": "SSRIs for Social Anxiety Disorder"}, {"name": "SSRIs for Pediatric Anxiety"}]}, {"name": "OCD", "children": [{"name": "SSRIs for Obsessive-Compulsive Disorder (OCD)"}, {"name": "SSRIs for OCD-like behaviors"}, {"name": "SSRIs for Pediatric OCD"}]}, {"name": "Weight and Eating Disorders", "children": [{"name": "SSRIs for Weight Management"}, {"name": "SSRIs for Eating Disorders"}]}, {"name": "Substance Abuse/Addictions", "children": [{"name": "SSRIs for Alcohol Dependence"}, {"name": "SSRIs for Substance Abuse (Cocaine)"}, {"name": "Behavioral Addictions"}, {"name": "SSRIs for Smoking Cessation"}]}, {"name": "OtherDisorders", "children": [{"name": "SSRIs for PTSD"}, {"name": "SSRIs for Pain"}, {"name": "SSRIs in Dementias"}, {"name": "SSRIs for Dermatological Diseases"}, {"name": "SSRIs for Generalized Anxiety Disorder (GAD)"}, {"name": "Premature Ejaculation"}, {"name": "SSRIs for Irritable Bowel Syndrome"}, {"name": "Hot Flushes (Menopause)"}, {"name": "SSRIs for Autism Spectrum Disorders"}, {"name": "SSRIs (Fluvoxamine) for Schizophrenia"}, {"name": "SSRIs for Body Dysmorphic Disorder (BDD)"}, {"name": "SSRIs Effects on Antimicrobials and Gut Microbiome"}, {"name": "SSRIs for Personality Disorders and Related Traits"}, {"name": "SSRIs for Fibromyalgia"}, {"name": "SSRIs for Enuresis"}, {"name": "SSRIs for Migraine"}, {"name": "SSRIs for Dysthymia"}, {"name": "SSRIs for Trichotillomania"}, {"name": "Paroxetines Therapeutic Potential as G Protein-coupled Receptor Kinase 2 (GRK2) Inhibitor for Cardiovascular Diseases"}, {"name": "SSRIs for Congenital Myasthenic Syndrome (SCCMS)"}, {"name": "Olfactory Bulbectomized (OB) Rat Model for Depression"}, {"name": "SSRIs for Tinnitus "}, {"name": "SSRIs for Syncope"}, {"name": "SSRIs for Narcolepsy"}, {"name": "SSRIs for Tourette's Syndrome"}, {"name": "SSRIs for Depersonalization Disorder"}, {"name": "Depression in Infertile Women"}, {"name": "SSRIs for Olfactory reference syndrome (ORS)"}]}]}, {"name": "OtherIndications", "children": []}]}, "safety": {"name": "Safety", "children": [{"name": "Special Populations", "children": [{"name": "Pediatrics", "children": [{"name": "Pediatric Depression"}, {"name": "SSRIs for Pediatric Anxiety"}, {"name": "Childhood Abuse and Depression Treatment Response"}, {"name": "SSRIs for Pediatric OCD"}]}, {"name": "Geriatrics", "children": [{"name": "SSRIs in Dementias"}, {"name": "Fracture Risk"}, {"name": "SSRIs for Depression with Cognitive Impairment"}, {"name": "SSRIs for Depression in Parkinsons Patients"}, {"name": "Drug Drug Interactions"}, {"name": "Hyponatremia Risk"}, {"name": "Geriatric Depression"}]}, {"name": "OtherPopulations", "children": [{"name": "Post-Stroke SSRI Use"}, {"name": "SSRIs and Cardiovascular Pathology"}, {"name": "SSRIs for Depression in Diabetes Patients"}, {"name": "SSRIs for Depression in in Epileptic Patients"}, {"name": "Depression in Hepatitis Patients"}, {"name": "SSRIs for Depression after Traumatic Brain Injury"}, {"name": "SSRIs for Depression in Cancer"}, {"name": "SSRIs for Depression in Kidney Disease Patients"}, {"name": "SSRIs for Depression in and Treatment of Multiple Sclerosis"}, {"name": "SSRIs for Depression in Chronic Obstructive Pulmonary Disease (COPD) Patients"}, {"name": "SSRIs for Depression in HIV-positive Patients"}]}]}, {"name": "Prenatal Exposure", "children": [{"name": "Risks of Prenatal Exposure"}, {"name": "Risks of Prenatal Exposure (Rodents)"}]}, {"name": "Pregnancy", "children": []}, {"name": "Suicide", "children": [{"name": "Pediatric Depression"}, {"name": "Suicice Risk"}]}, {"name": "Sexual Dysfunction", "children": [{"name": "Sexual Dysfunction"}, {"name": "Treatment of Paroxetine Induced Sexual Dysfunction"}]}, {"name": "Toxicity", "children": [{"name": "Serotonin Syndrome"}, {"name": "Hepatotoxic Risk"}, {"name": "Forensic Drug Concentration"}]}, {"name": "Cardiovascular", "children": [{"name": "SSRIs and Cardiovascular Pathology"}, {"name": "QTC Prolongation"}, {"name": "Pulmonary Hypertension"}]}, {"name": "OtherSafety", "children": [{"name": "Bleeding Risk"}, {"name": "Fracture Risk"}, {"name": "Extrapyramidal Reactions Risk"}, {"name": "Oncopreventive and Oncolytic Properties of SSRIs"}, {"name": "Drug Drug Interactions"}, {"name": "Hyponatremia Risk"}, {"name": "SSRI Safety Reviews"}, {"name": "Pulmonary Hypertension"}, {"name": "Withdrawal Symptoms"}, {"name": "Repeated SSRIs Exposures Effects on Dopamine Receptors"}, {"name": "Hyperprolactinemia-related Symptoms"}, {"name": "SRRIs and Ocular Safety"}, {"name": "SSRI-Induced Mania"}, {"name": "Risk for Orofacial Pain Disorders"}, {"name": "Risk of Hallucinations"}, {"name": "Adulterants in Weight Loss Supplements"}, {"name": "Risk of Microscopic Colitis"}, {"name": "Risk of Priapism"}, {"name": "Risk of Reversible Cerebral Vasoconstriction Syndrome (RCVS)"}]}]}, "other": {"name": "Other", "children": [{"name": "Drugs", "children": [{"name": "Fluvoxamine", "children": [{"name": "Fluvoxamine for Depression"}, {"name": "Fluvoxamine for Covid 19"}, {"name": "SSRIs (Fluvoxamine) for Schizophrenia"}]}, {"name": "Paroxetine", "children": [{"name": "Paroxetine Bindeing"}, {"name": "Paroxetine"}, {"name": "Treatment of Paroxetine Induced Sexual Dysfunction"}]}, {"name": "Fluoxetine", "children": [{"name": "Fluoxetine"}]}, {"name": "Escitalopram", "children": [{"name": "Escitalopram for Depression"}]}, {"name": "Citalopram", "children": [{"name": "Citalopram for Depression"}]}, {"name": "Sertraline", "children": [{"name": "(Sertraline) Drug Delivery"}, {"name": "Sertraline for Depression"}, {"name": "Sertraline"}]}, {"name": "Agomelatine", "children": [{"name": "Agomelatin for Depression"}]}, {"name": "Vilazodone", "children": [{"name": "Vilazodone for Depression"}]}, {"name": "Psilocybin", "children": [{"name": "Psilocybin for Depression"}]}, {"name": "Generic SSRIs", "children": [{"name": "Generic SSRIs"}]}, {"name": "SSRIs", "children": [{"name": "Selective serotonin reuptake inhibitors"}]}]}, {"name": "Ecotoxicology", "children": [{"name": "Aquatic Ecotoxicology"}, {"name": "Wastewater Management"}]}, {"name": "Alternative Treatments", "children": [{"name": "Herbal and Natural Compounds for Depression"}, {"name": "St. John's Wort for Depression"}]}, {"name": "Drug Utilization Patterns", "children": [{"name": "SSRI Utilization Patterns"}]}, {"name": "Cost-Effectineness", "children": [{"name": "Cost-Effectiveness"}]}, {"name": "OtherOther", "children": [{"name": "Hot Flushes (Menopause)"}, {"name": "SSRI Use"}, {"name": "Gatways to Clinical Trials"}, {"name": "Canine Behavioral Disorders"}, {"name": "Adulterants in Weight Loss Supplements"}, {"name": "Gateways to Clinical Trials"}, {"name": "Depression in Infertile Women"}, {"name": "SSRIs for Olfactory reference syndrome (ORS)"}]}]}}